Key Points
- Insider sale: Laura Williams sold 50,000 Ardelyx shares on Jan. 8 at an average $6.98 for ~$349,000, reducing her stake by about 12.15% to 361,563 shares (SEC filing).
- Bullish catalysts: The stock rally was driven by Ardelyx reporting preliminary 2025 product revenue of roughly $378 million and a bullish 2026 outlook, alongside a Piper Sandler upgrade and unusual call-option buying.
- Analyst and stock snapshot: Wall Street sentiment is largely positive with an average price target of $13.80 (Moderate Buy), the shares opened at $7.74, market cap ~$1.88 billion, and the company recently beat revenue expectations with $110.3 million for the quarter.
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura Williams sold 50,000 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $6.98, for a total transaction of $349,000.00. Following the completion of the sale, the insider owned 361,563 shares of the company's stock, valued at approximately $2,523,709.74. This represents a 12.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Ardelyx Stock Up 10.6%
Ardelyx stock opened at $7.74 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 4.41 and a quick ratio of 4.11. The company's 50-day moving average is $5.89 and its 200-day moving average is $5.48. The firm has a market capitalization of $1.88 billion, a PE ratio of -33.65 and a beta of 0.56. Ardelyx, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $8.05.
Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $0.00 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.06. The business had revenue of $110.33 million during the quarter, compared to analysts' expectations of $100.44 million. Ardelyx had a negative return on equity of 36.91% and a negative net margin of 14.20%.The business's revenue was up 14.6% compared to the same quarter last year. Sell-side analysts anticipate that Ardelyx, Inc. will post -0.18 earnings per share for the current year.
Hedge Funds Weigh In On Ardelyx
Hedge funds have recently bought and sold shares of the business. DCF Advisers LLC bought a new stake in Ardelyx in the 2nd quarter valued at about $39,000. Brighton Jones LLC acquired a new stake in shares of Ardelyx in the second quarter valued at approximately $40,000. SBI Securities Co. Ltd. raised its position in shares of Ardelyx by 147.0% in the third quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 6,102 shares in the last quarter. Swiss Life Asset Management Ltd bought a new stake in shares of Ardelyx in the third quarter valued at approximately $57,000. Finally, State of Wyoming acquired a new stake in Ardelyx during the second quarter worth approximately $61,000. 58.92% of the stock is owned by institutional investors.
Key Stories Impacting Ardelyx
Here are the key news stories impacting Ardelyx this week:
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on ARDX. TD Cowen raised their price target on Ardelyx from $9.00 to $10.00 and gave the company a "buy" rating in a report on Friday, October 31st. Citigroup raised their target price on shares of Ardelyx from $11.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday. BTIG Research lifted their target price on shares of Ardelyx from $14.00 to $17.00 and gave the stock a "buy" rating in a report on Friday. Raymond James Financial reissued a "strong-buy" rating and issued a $19.00 price target on shares of Ardelyx in a report on Thursday. Finally, Wedbush downgraded shares of Ardelyx from an "outperform" rating to a "hold" rating in a research report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Ardelyx currently has an average rating of "Moderate Buy" and an average price target of $13.80.
Check Out Our Latest Stock Analysis on Ardelyx
About Ardelyx
(
Get Free Report)
Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.
Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
